Our KRIS 6 Hooks Kid Reporter Lilly sat down with new catcher Garret Guillemette. The Hooks are on a 3-game road trip to San ...

India’s oil imports from US surged over 270% in first four months of year; one of the five ADMs recall the events following ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs Wegovy and Zepbound. This move undercuts the cash-pay market where these ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel ...

Eli Lilly's blockbuster diabetes treatment Mounjaro topped expectations for the first quarter, raking in $3.84 billion in revenue. That's up a whopping 113% from the same period a year ago.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership. Read more about LLY stock here.

What we know about Eli Lilly's orforglipron. If all goes well for Lilly, orforglipron could be up for FDA approval for weight management by the end of 2025, and for type 2 diabetes treatment in 2026.

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Here’s what to know about Eli Lilly’s pill, which still must go through a review process by the Food and Drug Administration to be approved for sale. When will the pill become available?